NYSEAMERICAN:NBY

NovaBay Pharmaceuticals Stock Forecast, Price & News

$1.23

+0.06 (+5.13 %)

(As of 02/24/2021 02:50 PM ET)

Add

Compare

Today's Range

$1.20

Now: $1.23▼

$1.30

50-Day Range

$0.57

MA: $0.66▼

$0.73

52-Week Range

$0.24

Now: $1.23▼

$1.94

Volume99,531 shs

Average Volume7.01 million shs

Market Capitalization$51.39 million

P/E RatioN/A

Dividend YieldN/A

Beta3.5

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Headlines

NovaBay CEO Issues Letter to Stockholders
February 8, 2021 | finance.yahoo.com

NovaBay Pharmaceuticals Now Included in EPA N Listing of Products That Kill SARS-CoV-2
December 14, 2020 | finance.yahoo.com

NovaBay Pharma rises 8% on Avenova distribution deal in Australia
November 23, 2020 | seekingalpha.com

NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
November 23, 2020 | finance.yahoo.com

41 Stocks Moving in Friday's Pre-Market Session
November 20, 2020 | msn.com

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript
November 12, 2020 | seekingalpha.com

NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 12, 2020 | finance.yahoo.com

NovaBay Announces Consumer Launch of CelleRx® Clinical Reset™
November 12, 2020 | finance.yahoo.com

A Preview Of NovaBay Pharmaceuticals's Earnings
November 11, 2020 | benzinga.com

Why NovaBay's Stock Is Trading Lower Today
November 3, 2020 | finance.yahoo.com

Why NovaBay's Stock Is Trading Lower Today
November 3, 2020 | benzinga.com

NovaBay Pharmaceuticals to Hold Third Quarter 2020 Conference Call on November 12
October 30, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:NBY

Previous Symbol

CUSIPN/A

CIK1389545

Webnovabay.com

Phone+1-510-8998800

Employees26

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio5.33

Quick Ratio5.07

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.60 million

Price / Sales7.79

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.03 per share

Price / Book41.00

Profitability

EPS (Most Recent Fiscal Year)($0.48)

Net Income$-9,650,000.00

Net Margins-122.78%

Return on Equity-309.15%

Return on Assets-93.80%

Miscellaneous

Outstanding Shares41,783,000

Market Cap$51.39 million

Next Earnings Date3/25/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.65 out of 5 stars

Medical Sector

1275th out of 1,958 stocks

Pharmaceutical Preparations Industry

577th out of 772 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for NovaBay Pharmaceuticals.

2.6 Community Rank

Outperform Votes
NovaBay Pharmaceuticals has received 246 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NovaBay Pharmaceuticals has received 220 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NovaBay Pharmaceuticals has received 52.79% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote “Outperform” if you believe NBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
NovaBay Pharmaceuticals does not currently pay a dividend.
Dividend Growth
NovaBay Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.80% of the stock of NovaBay Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 2.69% of the stock of NovaBay Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($0.32) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NovaBay Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NovaBay Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NovaBay Pharmaceuticals has a P/B Ratio of 41.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$1.23

+0.06 (+5.13 %)

(As of 02/24/2021 02:50 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What stocks does MarketBeat like better than NovaBay Pharmaceuticals?

Wall Street analysts have given NovaBay Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovaBay Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for NovaBay Pharmaceuticals.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.04. The biopharmaceutical company had revenue of $2.17 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 309.15% and a negative net margin of 122.78%.
View NovaBay Pharmaceuticals' earnings history.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

Shares of NovaBay Pharmaceuticals reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:

Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (Age 43, Pay $325.72k)
Mr. Andrew D. Jones, CFO & Treasurer
Ms. Wang Xu, Sr. Mang. & Controller (Age 38)

Who are some of NovaBay Pharmaceuticals' key competitors?

Some companies that are related to NovaBay Pharmaceuticals include Heat Biologics (HTBX), scPharmaceuticals (SCPH), Kindred Biosciences (KIN), Panacea Acquisition (PANA), Lantern Pharma (LTRN), Atossa Therapeutics (ATOS), Palatin Technologies (PTN), Assembly Biosciences (ASMB), FS Development (FSDC), Enochian Biosciences (ENOB), Aquestive Therapeutics (AQST), DiaMedica Therapeutics (DMAC), Citius Pharmaceuticals (CTXR), vTv Therapeutics (VTVT) and AcelRx Pharmaceuticals (ACRX).
View all of NBY's competitors.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.96%). Company insiders that own NovaBay Pharmaceuticals stock include Jian Ping Fu, Mijia Wu and Pharma (Hong Kong) Co Pioneer.
View institutional ownership trends for NovaBay Pharmaceuticals.

Which institutional investors are selling NovaBay Pharmaceuticals stock?

NBY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold NovaBay Pharmaceuticals company stock in the last year include Jian Ping Fu, and Mijia Wu.
View insider buying and selling activity for NovaBay Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $1.23.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals has a market capitalization of $51.39 million and generates $6.60 million in revenue each year. The biopharmaceutical company earns $-9,650,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does NovaBay Pharmaceuticals have?

NovaBay Pharmaceuticals employs 26 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

Where are NovaBay Pharmaceuticals' headquarters?

NovaBay Pharmaceuticals is headquartered at 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800 or via email at [email protected]

This page was last updated on 2/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here